EGFR inhibitors, including EGFR-tyrosine kinase inhibitors (TKIs) and anti-EGFR antibodies, can suppress cancer cell proliferation in NSCLC, CRC, and HNSCC, expressing aberrant EGFR ligands [5]. Here, EGFR is linked to head and neck squamous cell carcinoma.